Methylphenidate-induced acute orofacial and extremity dyskinesia.
Methylphenidate is a short-acting stimulant. In this article, the authors report a 7-year-old male patient who presented with orofacial and limb dyskinesia after his first dose of methylphenidate treatment for a diagnosis of attention-deficit/hyperactivity disorder; he was also receiving sodium valproate treatment for epilepsy. Orofacial dyskinesia appeared 5 hours after methylphenidate administration, persisted for 10 hours, and had completely resolved within 2 days. Although limb dyskinesia after methylphenidate is a commonly reported side effect, to the authors' knowledge this is only the second reported case to develop both orofacial and limb dyskinesia in the acute period after the first dose of methylphenidate. This case is reported to emphasize the potential side effects of methylphenidate, individual differences in drug sensitivities, and drug-receptor interactions via different mechanisms.
Department of Pediatrics, Faculty of Medicine, Fatih University, Ankara, Turkey.
Ayse Esra
AE
Yilmaz
Ahsen
A
Donmez
Emel
E
Orun
Tugba
T
Tas
Bunyamin
B
Isik
Fatma Mujgan
FM
Sonmez
D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis*; D017034:Epilepsy, Frontal Lobe / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D008297:Male; D008538:Meige Syndrome / Q000139:chemically induced* / Q000175:diagnosis*; D008774:Methylphenidate / Q000009:adverse effects* / Q000627:therapeutic use; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use
D000927:Anticonvulsants; D000697:Central Nervous System Stimulants; D008774:Methylphenidate; D014635:Valproic Acid